CSMD1 and esophageal squamous cell carcinoma: This phenomenon suggests that CSMD1 mutation may serve as an immune-related biomarker for predicting the ESCC patient’s prognosis and treatment response to paclitaxel [96].m6A modification study progressing is still at the initial stage and there are still many challenges.